What are the indications, dosing schedules, and contraindications for semaglutide (including its injectable and oral formulations) for weight management in adolescents and for type 2 diabetes in adults?

Semaglutide: Comprehensive Clinical Overview

Semaglutide is a highly effective GLP-1 receptor agonist available in both subcutaneous (SC) and oral formulations, FDA-approved for type 2 diabetes management and obesity treatment in adults and adolescents ≥12 years, with proven cardiovascular benefits including a 20% reduction in major adverse cardiovascular events. 1

FDA-Approved Indications

Type 2 Diabetes

• SC formulation: Approved in 2017 at doses of 1 mg and 2 mg weekly 1
• Oral formulation: Approved at 14 mg daily 1

Obesity/Weight Management

• SC formulation: 2.4 mg weekly approved for adults (2021) and adolescents ≥12 years (2022) 1
• Oral formulation: Phase III trials demonstrated efficacy at 25 mg and 50 mg daily for obesity, though currently FDA-approved only at 14 mg for diabetes 1

Cardiovascular Risk Reduction

• SC 2.4 mg weekly: Approved for secondary cardiovascular disease risk reduction based on the SELECT trial 1

---

Dosing Schedules

Subcutaneous Formulation

For Obesity (2.4 mg target):

• Start: 0.25 mg weekly 1, 2
• Titrate monthly as tolerated:
  • Week 1-4: 0.25 mg
  • Week 5-8: 0.5 mg
  • Week 9-12: 1.0 mg
  • Week 13-16: 1.7 mg
  • Week 17+: 2.4 mg (maintenance) 1

For Type 2 Diabetes (1-2 mg target):

• Start: 0.25 mg weekly for 4 weeks 2
• Increase to 0.5 mg weekly
• If additional glycemic control needed after ≥4 weeks, increase to 1 mg weekly 2
• Maximum approved dose for diabetes: 2 mg weekly 1

Administration details:

• Inject SC in abdomen, thigh, or upper arm 2
• Any time of day, with or without meals 2
• If dose missed, administer within 5 days 2

Oral Formulation

For Type 2 Diabetes:

• Start: 3 mg daily for 30 days 3
• Increase to 7 mg daily after 30 days
• If additional control needed, increase to 14 mg daily after another 30 days 3

Critical administration requirements:

• Take at least 30 minutes before first food, fluid, or other medications 3
• With no more than 120 mL plain water only 3
• Bioavailability is only ~1% (requires SNAC absorption enhancer) vs 89% for SC 4

---

Clinical Efficacy Data

Weight Loss Outcomes

SC Semaglutide 2.4 mg:

• STEP 1: 16.9% mean body weight reduction at 68 weeks 1
• STEP 5: 16.7% weight reduction maintained at 2 years 1
• 68% of participants achieved ≥5% weight loss 5

Oral Semaglutide:

• OASIS-1 (50 mg): 17.1% mean body weight reduction at 68 weeks 1
• Comparable efficacy to SC 2.4 mg formulation 4

In Type 2 Diabetes:

• Weight loss efficacy is dampened compared to obesity alone 1
• SCALE Diabetes: -5.8% vs -1.5% with placebo at 56 weeks 1

Glycemic Control

• SUSTAIN-FORTE: A1C reduction of 2.2% with SC 2.0 mg vs 1.9% with 1.0 mg 1
• Oral semaglutide 14 mg: A1C reductions of 0.9-1.4% depending on dose 6

Cardiovascular Benefits

SELECT Trial (landmark evidence):

• 20% reduction in 3-point MACE (nonfatal MI, nonfatal stroke, CV death) 1
• Mean exposure: 34 months, follow-up: 40 months 1
• First CVOT in obesity without diabetes 1
• Driven primarily by reduction in nonfatal stroke 1

Additional cardiometabolic benefits:

• Prevents progression from prediabetes to type 2 diabetes 1
• Prevents decline in renal function in T2D 1
• Ameliorates osteoarthritis and heart failure with preserved ejection fraction 1
• Improves MASH histology and fibrosis 1

---

Contraindications

Absolute Contraindications

• Personal or family history of medullary thyroid carcinoma 5
• Multiple endocrine neoplasia syndrome type 2 5
• Based on animal studies showing thyroid C-cell tumors 5

Relative Contraindications/Cautions

• History of pancreatitis (GLP-1 RAs associated with increased risk) 5
• Severe gastrointestinal disease
• Diabetic retinopathy (monitor closely)
• Renal impairment: No dose adjustment required for semaglutide across all levels of kidney function 3

---

Adverse Events and Mitigation

Gastrointestinal Effects (Most Common)

Incidence:

• Nausea: 15-20% with SC 2.4 mg, 5-13% with 7 mg 5
• Vomiting, diarrhea, constipation, abdominal pain 5
• Mostly mild-to-moderate, occur early, abate over time 5, 6

Mitigation strategy:

• Gradual dose titration is essential 5
• Monthly increases allow tolerance development 1
• 5.1-8.0% discontinue due to GI adverse events with higher doses 5

Serious Adverse Events

Pooled data from 8 RCTs:

• 38% higher risk of SAEs vs placebo (95% CI 1.10-1.73) 5
• Examples: pancreatitis, cholelithiasis, cholecystitis, acute MI, gastroenteritis, suicidal ideation 5

Hypoglycemia

• Minimal risk as monotherapy (glucose-dependent mechanism) 7
• Risk increases when combined with sulfonylureas or insulin 7
• Lower risk vs basal insulin (RR 0.53) 8

---

Special Populations

Adolescents (≥12 years)

• SC 2.4 mg approved for obesity with BMI ≥95th percentile and body weight ≥60 kg 1, 9
• New 1.7 mg maintenance dose approved November 2024 for adolescents 10
• Comparable exposure, tolerability, and efficacy to 2.4 mg in adolescents 10
• Mean BMI reduction: -15.2% with 1.7 mg vs -17.4% with 2.4 mg 10

Renal Impairment

• No dosage adjustments required at any level of kidney function 3
• Prevents decline in renal function in T2D at diabetes doses 1

Concomitant Medications

• Review and minimize weight-promoting medications when possible 11
• Examples to avoid: atypical antipsychotics (olanzapine, clozapine), tricyclic antidepressants, glucocorticoids, injectable progestins 11

---

Clinical Pearls and Pitfalls

Common Pitfalls to Avoid

1. Rapid titration: Increases GI adverse events and discontinuation 5
2. Abrupt discontinuation: Results in weight regain and worsening cardiometabolic risk factors 11
3. Inadequate patient education: Patients must understand lifelong therapy requirement for weight maintenance 11
4. Oral administration errors: Must take 30 minutes before anything else with minimal water 3

Optimization Strategies

Early response prediction:

• Weight reduction ≥4% at 16 weeks predicts 10.8% loss at 56 weeks (vs 3.0% without early response) 1
• Use this threshold to guide treatment continuation decisions

Long-term management:

• Continue therapy beyond weight loss goals to maintain benefits 11
• Weight management pharmacotherapy is indicated for chronic use 11
• If goals not met, intensify with additional approaches (metabolic surgery, additional agents, structured lifestyle programs) 11

Monitoring requirements:

• Screen for malnutrition in patients with significant weight loss 11
• Monitor for gallbladder disease (increased risk with GLP-1 RAs) 5
• Assess adherence and tolerance at each visit

---

Formulation Selection

Choose SC formulation when:

• Maximum weight loss efficacy needed (2.4 mg dose)
• Cardiovascular risk reduction indication
• Patient accepts weekly injections

Choose oral formulation when:

• Needle-averse patients 4
• Patient preference for daily oral medication
• Type 2 diabetes management (14 mg approved dose)
• Note: 25-50 mg doses show comparable efficacy to SC 2.4 mg but not yet FDA-approved for obesity 1, 4

Comparative efficacy:

• Oral 50 mg: -15.1% body weight at 68 weeks 4
• SC 2.4 mg: -14.9% body weight at 68 weeks 4
• Clinically equivalent outcomes with different administration routes 4, 12